Ferric Carboxymaltose in Iron-Deficient Patients with Hospitalized Heart Failure and Reduced Kidney Function
Open Access
- 29 June 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 18 (9) , 1124-1134
Abstract
Background: Reduced kidney function is common among patients with heart failure. In patients with heart failure and/or kidney disease, iron deficiency is an independent predictor of adverse outcomes. In the AFFIRM-AHF trial, patients with acute heart failure with iron deficiency treated with intravenous ferric carboxymaltose demonstrated reduced risk of heart failure hospitalization, with improved quality of life. We aimed to further characterize the impact of ferric carboxymaltose among patients with coexisting kidney impairment. Methods: The double-blind, placebo-controlled AFFIRM-AHF trial randomized 1132 stabilized adults with acute heart failure (left ventricular ejection fraction <50%) and iron deficiency. Patients on dialysis were excluded. The primary end point was a composite of total heart failure hospitalizations and cardiovascular death during the 52-week follow-up period. Additional end points included cardiovascular hospitalizations, total heart failure hospitalizations, and days lost to heart failure hospitalizations or cardiovascular death. For this subgroup analysis, patients were stratified according to baseline eGFR. Results: Overall, 60% of patients had an eGFR 0.05). Conclusions: In a cohort of patients with acute heart failure, left ventricular ejection fraction <50%, and iron deficiency, the safety and efficacy of ferric carboxymaltose were consistent across a range of eGFR values. Clinical Trial registry name and registration number: Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency (Affirm-AHF), NCT02937454.Keywords
This publication has 39 references indexed in Scilit:
- Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysisInternational Journal of Cardiology, 2013
- Iron deficiency in chronic heart failure: An international pooled analysisAmerican Heart Journal, 2013
- Mineral metabolism and outcomes in chronic kidney disease stage 2–4 patientsBMC Nephrology, 2013
- Beyond the Cardiorenal Anaemia Syndrome: Recognizing the Role of Iron DeficiencyEuropean Journal of Heart Failure, 2012
- Iron Deficiency Predicts Impaired Exercise Capacity in Patients With Systolic Chronic Heart FailureJournal of Cardiac Failure, 2011
- Disordered Iron Homeostasis in Chronic Heart FailureJACC, 2011
- Phosphate Metabolism in CKD Stages 3–5: Dietary and Pharmacological ControlInternational Journal of Nephrology, 2011
- Rationale and Design of Ferinject® Assessment in Patients with IRon Deficiency and Chronic Heart Failure (FAIR-HF) Study: A Randomized, Placebo-Controlled Study of Intravenous Iron Supplementation in Patients with and without AnaemiaEuropean Journal of Heart Failure, 2009
- Admission or Changes in Renal Function During Hospitalization for Worsening Heart Failure Predict Postdischarge SurvivalCirculation: Heart Failure, 2008
- Renal Impairment and Outcomes in Heart FailureJACC, 2006